Results 301 to 310 of about 101,548 (353)
Some of the next articles are maybe not open access.
Diabetes/Metabolism Research Reviews, 2023
This study aimed to evaluate the effects of Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) on prediabetes with overweight/obesity.
Weihao Wang +5 more
semanticscholar +1 more source
This study aimed to evaluate the effects of Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) on prediabetes with overweight/obesity.
Weihao Wang +5 more
semanticscholar +1 more source
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Advances in Chronic Kidney Disease, 2021In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with their marked glucose-lowering actions, which occur both at fasting and in the postprandial phase without an increased ...
Tricò, Domenico, Solini, Anna
openaire +3 more sources
Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Kardiologiia, 2014In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov +2 more
openaire +2 more sources
Obesity and Glucagon-Like Peptide-1 Receptor Agonists
JAMAThis Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti +2 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
Trends in Endocrinology & Metabolism, 2016Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on ...
van Raalte, Daniël H, Verchere, C Bruce
openaire +4 more sources
Diabetes, obesity and metabolism
To assess the level of adherence to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) treatment using real‐world data and to investigate the sociodemographic and clinical factors associated with discontinuation of GLP‐1RAs.
M. Lassen +8 more
semanticscholar +1 more source
To assess the level of adherence to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) treatment using real‐world data and to investigate the sociodemographic and clinical factors associated with discontinuation of GLP‐1RAs.
M. Lassen +8 more
semanticscholar +1 more source
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
JAMAThis Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Sadiya S, Khan +2 more
openaire +2 more sources
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Journal of Clinical PsychopharmacologyThe glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire +3 more sources
Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function
Heart, Lung and Circulation, 2021Prevention of cardiovascular events and regression of atherosclerotic changes are the primary aims of preventive cardiovascular medicine. Arterial thrombosis is caused by endothelial dysfunction, which disrupts vascular haemostasis. Glucagon-like peptide 1 (GLP-1) receptor agonists have been initially used as glucose lowering agents, but over time have
Edin Begic, Mirsada Causevic
openaire +2 more sources